Galapagos Acquires Cangenix

Galapagos NV and Cangenix Ltd have announced that Galapagos has acquired Cangenix to add structure-based drug discovery to the Argenta service offering.

Cangenix’s technology will augment Argenta’s ability to design new drugs and fill a growing client need.

Under the terms of the acquisition agreement, Galapagos will pay a total cash consideration of £1 million, with a further £440,000 potential earn out payment contingent upon achievement of certain conditions.

Argenta will integrate all of Cangenix’s assets, know-how, personnel and service contracts. The activities will be added to Argenta’s capabilities in hit finding and medicinal chemistry.

The Cangenix team of 4 staff will join Argenta but will continue to operate the platform in its premises in Canterbury, securing a smooth transition of the business. The acquisition will contribute to the Argenta revenues and profit for 2013.

“We welcome the Cangenix team and their clients to the Galapagos group,” said Onno van de Stolpe, CEO of Galapagos. “The assets and expertise of Cangenix really address a growing client need at Argenta. We look forward to extending and expanding this business.”

RELATED ARTICLES

The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.

Researchers have succeeded in developing a chemical process to absorb infrared light and re-emit it as visible energy, allowing innocuous radiation to penetrate living tissue and other materials without the damage caused by high-intensity light exposure.